Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos MV, Dall'Olio D, van de Donk NWCJ, Jackson G, Rocchi S, Salwender H, Bladé Creixenti J, van der Holt B, Castellani G, Bonello F, Capra A, Mai EK, Dürig J, Gay F, Zweegman S, Cavo M, Kaiser MF, Goldschmidt H, Hernández Rivas JM, Larocca A, Cook G, San-Miguel JF, Boccadoro M, Sonneveld P. D'Agostino M, et al. Among authors: lahuerta jj. J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605179 Free article.
Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A, Granda A, Martínez-Chamorro C, Díaz-Mediavilla J, Martínez R, García-Laraña J, Lahuerta JJ, Sureda A, Bladé J, de la Rubia J, Fernández-Rañada JM, San Miguel J; Spanish Registry of Transplants in Multiple Myelomas; Spanish Group of Hemopoietic Transplant (GETH); PETHEMA. Alegre A, et al. Among authors: lahuerta jj. Haematologica. 2002 Jun;87(6):609-14. Haematologica. 2002. PMID: 12031917
High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
Caballero MD, Pérez-Simón JA, Iriondo A, Lahuerta JJ, Sierra J, Marín J, Gandarillas M, Arranz R, Zuazu J, Rubio V, Fernández de Sevilla A, Carreras E, García-Conde J, García-Laraña J, Grande C, Sureda A, Vidal MJ, Rifón J, Pérez-Equiza C, Varela R, Moraleda JM, García Ruíz JC, Albó C, Cabrera R, San Miguel JF, Conde E. Caballero MD, et al. Among authors: lahuerta jj. Ann Oncol. 2003 Jan;14(1):140-51. doi: 10.1093/annonc/mdg008. Ann Oncol. 2003. PMID: 12488306 Free article.
Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Osea phase II trial.
Lahuerta JJ, Grande C, Martínez-Lopez J, De La Serna J, Toscano R, Ortiz MC, Larregla S, Conde E, Insunza A, Gonzalez-San Miguel JD, Bargay J, Cabrera R, García-Ruiz JC, Albó C, García-Alonso L, Solano F, Vivancos P, León A, San Miguel J; Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Osea. Lahuerta JJ, et al. Br J Haematol. 2003 Jan;120(2):296-303. doi: 10.1046/j.1365-2141.2003.04067.x. Br J Haematol. 2003. PMID: 12542490 Free article. Clinical Trial.
Genetic abnormalities and patterns of antigenic expression in multiple myeloma.
Mateo G, Castellanos M, Rasillo A, Gutiérrez NC, Montalbán MA, Martín ML, Hernández JM, López-Berges MC, Montejano L, Bladé J, Mateos MV, Sureda A, de la Rubia J, Díaz-Mediavilla J, Pandiella A, Lahuerta JJ, Orfao A, San Miguel JF. Mateo G, et al. Among authors: lahuerta jj. Clin Cancer Res. 2005 May 15;11(10):3661-7. doi: 10.1158/1078-0432.CCR-04-1489. Clin Cancer Res. 2005. PMID: 15897562
Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
Sarasquete ME, García-Sanz R, González D, Martínez J, Mateo G, Martínez P, Ribera JM, Hernández JM, Lahuerta JJ, Orfão A, González M, San Miguel JF. Sarasquete ME, et al. Among authors: lahuerta jj. Haematologica. 2005 Oct;90(10):1365-72. Haematologica. 2005. PMID: 16219573
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J, Bladé J, Lahuerta JJ, Ribera JM, Martínez R, Alegre A, García-Laraña J, Fernández P, Sureda A, de Arriba F, Carrera D, Besalduch J, García Boyero R, Palomera Bernal L, Hernández MT, García PR, Pérez-Calvo J, Alcalá A, Casado LF, San Miguel J. de la Rubia J, et al. Among authors: lahuerta jj. Haematologica. 2006 May;91(5):621-7. Epub 2006 Apr 19. Haematologica. 2006. PMID: 16627253 Clinical Trial.
Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myeloma.
Martinez-Lopez J, Martinez-Sanchez P, Garcia-Sanz R, Sarasquete ME, Ayala R, Gonzalez M, Bautista JM, Gonzalez D, San Miguel J, Garcia-Effron G, Lahuerta JJ. Martinez-Lopez J, et al. Among authors: lahuerta jj. J Mol Diagn. 2006 Jul;8(3):364-70. doi: 10.2353/jmoldx.2006.050101. J Mol Diagn. 2006. PMID: 16825510 Free PMC article.
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.
Gutiérrez NC, Castellanos MV, Martín ML, Mateos MV, Hernández JM, Fernández M, Carrera D, Rosiñol L, Ribera JM, Ojanguren JM, Palomera L, Gardella S, Escoda L, Hernández-Boluda JC, Bello JL, de la Rubia J, Lahuerta JJ, San Miguel JF; GEM/PETHEMA Spanish Group. Gutiérrez NC, et al. Among authors: lahuerta jj. Leukemia. 2007 Jan;21(1):143-50. doi: 10.1038/sj.leu.2404413. Epub 2006 Oct 5. Leukemia. 2007. PMID: 17024116 Clinical Trial.
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
Rosiñol L, Oriol A, Mateos MV, Sureda A, García-Sánchez P, Gutiérrez N, Alegre A, Lahuerta JJ, de la Rubia J, Herrero C, Liu X, Van de Velde H, San Miguel J, Bladé J. Rosiñol L, et al. Among authors: lahuerta jj. J Clin Oncol. 2007 Oct 1;25(28):4452-8. doi: 10.1200/JCO.2007.12.3323. Epub 2007 Sep 4. J Clin Oncol. 2007. PMID: 17785704 Clinical Trial.
195 results